Exin Therapeutics
YC W25San Francisco, US · Founded 2024 · Delaware corporation · 9 employees · 2 known investors
Exin Therapeutics develops an AI-guided drug discovery platform that uses experimental mouse studies to identify neurological therapies, starting with epilepsies linked to autism and Parkinson's disease. The company trains machine learning models on proprietary multimodal neuroscience data to guide its therapeutic screening process.
Also known as EI Therapeutics
Founders & leadership· Y Combinator alumni (W25)
Exin Therapeutics was founded in 2024 by Gabriel Ocana Santero, Marko Tvrdic, and Ivan Alex Priela Lazarte.
GO
Gabriel Ocana Santeroin𝕏CEO and Co-founderGabriel Ocana Santero holds an MSc in Neuroscience and PhD in Pharmacology from Oxford University, with research experience spanning gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. He has conducted work on neurodevelopment and serotonin signaling at the Gatsby Unit at UCL, and now develops gene therapies for neurological conditions at Exin Therapeutics.
MT
Marko Tvrdicin𝕏Co-Founder & COOHe holds an MSc and PhD from Oxford and has research experience across molecular biology, neuroscience disciplines including retinal disorders, circadian biology, and neurodevelopment, with prior exposure to venture capital.
IA
Ivan Alex Priela LazarteCo-founder
Investors · 2
Reported raises · per SEC filings
Form D private placements$2.2M disclosed across 1 round · 2024
▶$2.2MraisedFeb 2026 · 28 investors · BiotechnologyRule 506(b)
▶$2.2MraisedFeb 2026 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gabriel Ocana SanteroExecutive Officer, Director
- Ivan Alex Priela LazarteExecutive Officer, Director
- Marko TvrdicExecutive Officer, Director
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Images
Competitors · 7
by search overlap
Enliven Therapeutics4 shared keywordsEnliven Therapeutics is a biopharmaceutical company developing small molecule precision therapeutics, including ELVN-001, a selective active site inhibitor of BCR::ABL1 for patients with chronic myeloid leukemia (CML). It focuses on drug candidates with differentiated profiles across efficacy, tolerability, and dosing for clinical use.
Clementia3 shared keywordsIpsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
Iteriontherapeutics3 shared keywordsIterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway. Its lead candidate is in clinical trials for advanced hepatocellular carcinoma and other Wnt-driven tumors such as colorectal cancer.
Sentynl3 shared keywordsSentynl Therapeutics is a pharmaceutical company that develops and commercializes prescription therapies, including ZYCUBO (copper histidinate), which has received FDA approval. It provides access, support, and medical affairs services for its products.
Bioworld3 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Intracellular Therapies3 shared keywordsIntra-Cellular Therapies develops treatments for neuropsychiatric, neurologic, and related disorders, including its product CAPLYTA. The company is now part of Johnson & Johnson.
Click Therapeutics3 shared keywordsClick Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.
Companies competing with Exin Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Exin Therapeutics do?
- Exin Therapeutics develops an AI-guided drug discovery platform that uses experimental mouse studies to identify neurological therapies, starting with epilepsies linked to autism and Parkinson's disease. The company trains machine learning models on proprietary multimodal neuroscience data to guide its therapeutic screening process.
- Who founded Exin Therapeutics?
- Exin Therapeutics was founded by Gabriel Ocana Santero, Marko Tvrdic, Ivan Alex Priela Lazarte in 2024.
- Who are Exin Therapeutics's investors?
- Exin Therapeutics's investors include Y Combinator, 468 Capital.
- How much funding has Exin Therapeutics raised?
- Exin Therapeutics has disclosed $2.2M raised across 1 round.
- Where is Exin Therapeutics headquartered?
- Exin Therapeutics is headquartered in San Francisco, US.